Global Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment (Selective Serotonin Reuptake Inhibitor, Serotonin-Norepinephrine Reuptake Inhibitor, Benzodiazepines, Tricyclic Antidepressants, and Others) and Non-drug Treatment (Nutritional Therapy, Behavioral Therapy, and Others)), by Route of Administration (Oral, Intravenous, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 455.7 million in 2020 and is estimated to exhibit a CAGR of 5.2% during the forecast period (2020-2027).
The increasing prevalence of mental disorders among the population, may lead to increasing prevalence of eating disorders, which is expected to support growth of market over the forecast period. For instance, according to the World Health Organization: 30th January 2020, globally, depression is one of the most common mental disorder and around 264 million people are affected from depression. Moreover, according to the same source, around 76% and 85% of people in low and middle income countries do not receive any treatment for depression. This may lead to increasing prevalence of eating disorders among the population.
Market players are engaged in receiving approvals from the regulatory authorities which is an important step for launching the product in the market. For instance, in 2017, Alembic Pharmaceuticals Ltd received the U.S. Food and Drug Administration (U.S. FDA) approval for its generic anti-depressant Fluoxetine tablets, which will allow the manufacture and marketing of the Fluoxetine tablets of strengths 10 mg and 20 mg. The product is the generic version of Eli Lily and Company’s Prozac tablets.
Global Bulimia Nervosa Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID – 19 pandemic is expected to hamper growth of the global bulimia nervosa treatment market during the forecast period. The coronavirus cases are increasing at a very high rate across the globe. According to World Health Organization, on November 26, 2020, globally, 60,074,174 confirmed cases of COVID-19 and 1,416,292 deaths due to COVID-19 were reported.
According to the National Health Service (NHS), 14th June 2020, in the U.K., due to COVID-19 pandemic and lockdown, it was estimated that around 1.3 million people are suffering from eating disorders and out of these, 87% patients reported about worsening of the symptoms and around 73% of the patients approached the emergency department for the treatment of the eating disorders.
Browse 35 Market Data Tables and 28 Figures spread through 156 Pages and in-depth TOC on, Global Bulimia Nervosa Treatment, by Treatment Type (Drug Treatment (Selective Serotonin Reuptake Inhibitor, Serotonin-Norepinephrine Reuptake Inhibitor, Benzodiazepines, Tricyclic Antidepressants, and Others), Non-drug Treatment (Nutritional Therapy, Behavioral Therapy, and Others)), by Route of Administration (Oral, Intravenous, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
To know the latest trends and insights prevalent in the bulimia nervosa treatment market, click the link below:
https://www.coherentmarketinsights.com/market-insight/bulimia-nervosa-treatment-market-4323
Market players are involved in conducting seminars for finding the way for developing treatment options for patients suffering from eating disorders. For instance, in 2016, Johnson & Johnson and Janssen Neuroscience collaboratively hosted Eating Disorder Leadership Summit, in the U.S., where several pioneer leaders were involved for discussing new treatment options for the patients suffering from eating disorders such as bulimia nervosa, binge eating disorders, and others. The discussion was focused on developing new effective and affordable treatment options for the patients suffering from eating disorders.
Key Takeaways of the Bulimia Nervosa Treatment:
- The global bulimia nervosa treatment market is expected to exhibit a CAGR of 5.2% over the forecast period (2020-2027), owing to growth in potential markets, especially in Europe. North America accounted for major market share.
- Market players are indulged in initiating the studies for the research and development of new treatment options for eating disorder, which is expected to drive the market growth over the forecast period. For instance, in 2018, Eating Recovery Center LLC’s, Binge Eating Treatment and Recovery Program, initiated a new study for developing treatment option for successful reduction and complete abstinence from binge eating and other disorders such as binge eating disorder (BED) and bulimia nervosa.
- Some of the major players operating in the global bulimia nervosa treatment market include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
